Clinical trials: IgAVN
IgAN, IgAVN
Study of Ravulizumab in Pediatric Participants With Primary IgAN
The primary objectives of this study are to characterize ravulizumab pharmacokinetics (PK) and pharmacodynamics (PD), and to evaluate safety and efficacy following ravulizumab IV dosing in pediatric participants with IgAN or…
- Conditions
- IgAN, IgAVN, Immunoglobulin A Nephropathy, Immunoglobulin A Vasculitis Associated Nephritis
- Trial name
- NCT07024563
- Testing
- Ravulizumab
- Where
- 15 sites in United States, China and 5 more
- Volunteers
- 36 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
IgAVN, IgA Vasculitis
Telitacicept in the Treatment of Pediatric IgA Vasculitis-Associated Nephritis
To further evaluate the efficacy and safety of Telitacicept in the treatment of pediatric IgA vasculitis nephritis (IgAVN) within real-world settings, this study employs a multicenter, retrospective and prospective observational…
- Trial name
- NCT07354503
- Testing
- Collect clinical data from the patients., This study exclusively prospectively collected clinical data from the patients and did not involve any therapeutic interventions
- Volunteers
- 300 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
IgA Nephropathy (IgAN), IgAVN
Clinical Study on the Efficacy and Safety of Telitacicept in the Treatment of Pediatric IgA Nephropathy or IgA Vasculitis Nephritis
This clinical trial is a prospective, multicenter, non-randomized controlled study designed to evaluate the efficacy and safety of Telitacicept, a novel biologic agent, in treating pediatric IgA Nephropathy (IgAN) and IgA…
- Trial name
- NCT07052981
- Testing
- Telitacicept
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Guixia Ding